About the Journal
Focus and Scope
Progress in Drug Discovery & Biomedical Science (PDDBS) is an open access journal dedicated to the exchange of information and understandings about the research in areas of drug discovery and biomedical science based on the principles established through international conventions.
PDDBS covering both the fundamental and application aspects of drug discovery & biomedical science and welcoming papers having a good interdisciplinary approach.
-Plant, microbes bioactives
-Basic or applied biomedical research
-Toxicology & pharmacology
- Molecular/cell biology
- Drug delivery
- Therapeutic strategies/targets
- Clinical trials
- Structural Biology and Biomolecular Modeling
- Curriculum, instruction and pedagogy
The publication frequency of Progress in Drug Discovery and Biomedical Science is annually.
Peer Review Process
Journal Publication Ethics
Progress in Drug Discovery and Biomedical Science's manuscript management adheres to “Code of Conduct for Journal Editors and Code of Conduct for Publishers” and Best Practise as stipulated by the Committee on Publication Ethics (COPE) to prevent misconduct of research papers. The editorial committee consider the ethical publishing practices as fundamental part of ethical responsibilities among authors. The editors are committed to maintaining high standards through a rigorous double-blinded peer review along with strict ethical policies. In order to avoid the plagiarism, the author shall provide all the information about the novelty and importance of the findings including the similarity index report by iThenticate/Turnitin of 30% or less. In addition, the editor of the journal is doing our best to ensure fair, unbiased, and transparent peer review and editorial decisions. When an author discovers a significant error or inaccuracy in his/her own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper. Any detected cases of misconduct, whether on the part of authors, reviewers or editors, will be vigorously pursued. And finally, each article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under: i. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted; ii. This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes; iii. The author(s) permits HH Publisher to publish this article that has not been submitted elsewhere.
Open Access Policy
Progress in Drug Discovery and Biomedical Science is a Gold Open access journal. Author(s) shall retain the copyright of their work, but grant to the Publisher a license to publish.
Progress in Drug Discovery and Biomedical Science works under the license of Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) that allows copying, distribution, and transmission of the published work with the acknowledgement of original creator. This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types.
Article Processing Charge
If the manuscript is accepted for publication, the author requires paying for an Article Publication Charge (APC) to cover publication costs.
APC is USD40 or RM150.
Progress in Drug Discovery and Biomedical Science is financially supported by Open-Access model system under the HH Publisher. Business models or revenue sources (e.g., author fees, subscriptions, advertising, reprints, institutional support, and organizational support) shall be clearly stated or otherwise evident on the journal’s website. Publishing fees or waiver status should not influence editorial decision making.
Progress in Drug Discovery and Biomedical Science shall state the advertising policy if relevant, including what types of adverts will be considered, who makes decisions regarding accepting adverts and whether they are linked to content or reader behaviour (online only) or are displayed at random. Advertisements should not be related in any way to editorial decision making and shall be kept separate from the published content.
Any direct marketing activities, including solicitation of manuscripts that are conducted on behalf of the Progress in Drug Discovery and Biomedical Science, shall be appropriate, well targeted, and unobtrusive. Information provided about the publisher or journal is expected to be truthful and not misleading for readers or authors.